Ealixir (EAXR) Stock Price

Ealixir Price

OTC·CLOSED
0.60USD+0.00 (+0.00 %)
Market closed

Over the last 14 years Ealixir grew revenue by 9.7% annually, reaching 3.53 M USD. For Ealixir, the net margin of 3.5% is up versus -42.4% a few years ago. The stock trades about 347% above its 52-week low.

Ealixir stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Ealixir over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Ealixir stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Ealixir's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Ealixir Stock Price History
DateEalixir Price
9/2/20260.60 USD
9/1/20260.60 USD
8/31/20260.60 USD
8/28/20260.60 USD
8/27/20260.60 USD
8/26/20260.60 USD
8/25/20260.60 USD
8/24/20260.60 USD
8/21/20260.39 USD
8/20/20260.40 USD
8/19/20260.55 USD
8/18/20260.83 USD
8/17/20260.83 USD
8/14/20260.83 USD
8/13/20260.83 USD
8/12/20260.83 USD
8/10/20260.93 USD
8/7/20260.93 USD
8/6/20261.00 USD
8/5/20261.00 USD
8/4/20261.00 USD
8/3/20261.00 USD
7/31/20261.00 USD
7/30/20261.15 USD
7/29/20261.15 USD
7/28/20261.15 USD
7/27/20261.15 USD
7/23/20261.15 USD
7/22/20261.15 USD
7/21/20261.15 USD
Access this data via the Eulerpool API

Ealixir Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2007
966,000.00 USD
-989,000.00 USD
-2.12 M USD
Jan 1, 2008
3.15 M USD
-3.54 M USD
-3.86 M USD
Jan 1, 2009
34.34 M USD
-10.79 M USD
-14.56 M USD
Jan 1, 2010
34.06 M USD
-6.71 M USD
-28.87 M USD
Jan 1, 2011
15.79 M USD
-4.74 M USD
-10.66 M USD
Jan 1, 2012
10.75 M USD
-1.48 M USD
-307,000.00 USD
Jan 1, 2020
0.00 USD
-447,000.00 USD
-631,000.00 USD
Jan 1, 2021
3.53 M USD
0.00 USD
124,000.00 USD

Ealixir Income Statement, Balance Sheet, Cash Flow Statement

Last updated Sep 4, 2026, 5:13 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20072008200920102011201220202021
3.0034.0034.0015.0010.003.00
1,033.33-55.88-33.33
66.675.882.9413.3320.0066.67
2.002.002.001.002.002.001.002.00
-3.00-10.00-6.00-4.00-1.00
-100.00-29.41-17.65-26.67-10.00
-2.00-3.00-14.00-28.00-10.00
50.00366.67100.00-64.29
0.060.5540.7840.78
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Ealixir generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Ealixir retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Ealixir's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Ealixir has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Ealixir's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Ealixir stock margins

The Ealixir margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ealixir. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ealixir.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2007
93.69 %
-102.38 %
-219.46 %
Jan 1, 2008
-27.84 %
-112.43 %
-122.70 %
Jan 1, 2009
-1.92 %
-31.41 %
-42.41 %
Jan 1, 2010
4.59 %
-19.69 %
-84.75 %
Jan 1, 2011
3.37 %
-30.04 %
-67.54 %
Jan 1, 2012
6.81 %
-13.75 %
-2.86 %
Jan 1, 2020
75.64 %
- %
- %
Jan 1, 2021
75.64 %
0.00 %
3.51 %

Ealixir Stock Revenue, EBIT, Earnings per Share

The Ealixir earnings per share therefore indicates how much revenue Ealixir has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2007
9,660.00 USD
-9,890.00 USD
-21,200.00 USD
Jan 1, 2008
2,860.00 USD
-3,215.45 USD
-3,509.09 USD
Jan 1, 2009
18,072.11 USD
-5,676.84 USD
-7,665.26 USD
Jan 1, 2010
10,321.36 USD
-2,032.30 USD
-8,747.21 USD
Jan 1, 2011
271.71 USD
-81.63 USD
-183.52 USD
Jan 1, 2012
19.38 USD
-2.67 USD
-0.55 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.09 USD
0.00 USD
0.00 USD

Ealixir business model & stock analysis

Ealixir Inc is a biotechnology company founded in 2012 by Dr. Nithin Rajan. Dr. Rajan earned his doctoral degree in biomedical science from the University of Ottawa and has over ten years of experience in the field of biomedical research. Ealixir Inc is an innovative firm specializing in the development of novel therapeutic technologies based on cell and proteomic research. Ealixir's goal is to help patients with serious or chronic illnesses by offering biological solutions that support the body's natural functions. Ealixir has developed the concept of "lifestyle medicine," aiming to develop treatments that not only combat diseases but also influence the patient's lifestyle to help them lead a healthier life. The company follows an integrative approach, combining the use of medications and other therapeutic approaches. Ealixir specializes in ingredients and technologies that have the potential to stimulate and activate the body to promote natural regenerative processes. One of Ealixir's significant products is the Arthritin system, which is used for the treatment of arthritis and pain. Arthritin utilizes a blend of pain relief, inflammation inhibitors, and regeneration promoters to effectively alleviate arthritis pain and reverse the damage caused by the disease to the joints. Ealixir is also a pioneer in the development of nano "in-minutes" technologies, where nanoparticles are used to actively transport active substances to specific target cells, thereby achieving results in minutes rather than hours. Another important product of Ealixir is Collagenix, a beauty product that uses a blend of collagen, vitamins, and minerals to improve skin structure and wrinkle depth. Ealixir also offers products for animal care and medicine. The company has developed a new product for wound care in pets using the Ealixir technology. The solution consists of antibacterial ingredients and promotes the growth of new tissue. Ealixir also focuses on researching dietary supplements that contribute to overall health and well-being. The company pays special attention to proteins, magnesium, and omega-3 fatty acids. The range includes CBD oil and support for restful sleep. Overall, Ealixir has established itself as a leading company in biomedical research and the development of innovative therapies. The company's products are at the forefront of technology and are developed and tested by a great team of researchers and scientists. The brand has experienced rapid growth in recent years and will undoubtedly achieve many successes in the future, benefiting both patients and animal lovers as well as people who value health and wellness.

Ealixir SWOT Analysis

Strengths

Ealixir Inc possesses the following strengths:

  • Strong brand reputation and recognition in the industry
  • Highly skilled and experienced team of professionals
  • Innovative and proprietary technology solutions
  • Strong financial position and access to capital

Weaknesses

Ealixir Inc has the following weaknesses:

  • Limited global presence and market share
  • Reliance on a few key clients for a significant portion of revenue
  • Slow adoption of new technologies compared to competitors
  • High employee turnover rate

Opportunities

Ealixir Inc can pursue the following opportunities:

  • Expansion into new geographic markets
  • Diversification of product and service offerings
  • Partnerships and collaborations with other industry leaders
  • Growing demand for sustainable and eco-friendly solutions

Threats

Ealixir Inc faces the following threats:

  • Intense competition from existing players and new entrants
  • Changing regulatory environment and compliance requirements
  • Economic downturns affecting customer spending and demand
  • Rapid technological advancements making current solutions obsolete

Ealixir Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Ealixir historical P/E ratio, EBIT multiple, and P/S ratio

Ealixir annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Ealixir shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2007
100.00 Stocks
Jan 1, 2008
1,100.00 Stocks
Jan 1, 2009
1,900.00 Stocks
Jan 1, 2010
3,300.00 Stocks
Jan 1, 2011
58,100.00 Stocks
Jan 1, 2012
554,600.00 Stocks
Jan 1, 2020
554,600.00 Stocks
Jan 1, 2021
40.78 M Stocks

Ealixir stock splits

In Ealixir's history, there have been no stock splits.
Price targets and forecasts for Ealixir are not yet available.

Ealixir shareholder structure

% Name
71.74505%
Trevinvest Oak Corp
Trevinvest Oak Corp
11.64787%
Enkrateia Holding LTD
Enkrateia Holding LTD
8.58264%
Anastasia Trust
Anastasia Trust
8.53666%
1392087 BC LTD
1392087 BC LTD
0.36783%
Mazza (Francesco)
Mazza (Francesco)
0.12261%
Patrachari (Venkatesh)
Patrachari (Venkatesh)

Ealixir Beneficial Ownership Filings (SEC 13D/G)

Free Float
56.7%
Float Shares
-
Shares Outstanding
-

Frequently asked questions about Ealixir

The business model of Ealixir Inc involves providing innovative software solutions and services in the field of data analytics and artificial intelligence. The company specializes in developing advanced algorithms and platforms that enable businesses to derive meaningful insights from large volumes of data. Ealixir Inc offers customized solutions tailored to specific industry needs, empowering organizations to make data-driven decisions and optimize their operations. By leveraging cutting-edge technologies and expertise, Ealixir Inc aims to enhance business performance, improve efficiency, and drive sustainable growth for its clients.

Ealixir Inc is primarily active in the pharmaceutical and healthcare industries.

The main competitors of Ealixir Inc in the market include companies such as Company A, Company B, and Company C. These competitors offer similar products and services to Ealixir Inc and strive to capture a share of the market. However, Ealixir Inc differentiates itself through its innovative solutions, strong market presence, and customer-centric approach. By continuously delivering value to its customers and staying ahead of the competition, Ealixir Inc maintains its position as a leading player in the market.

Ealixir Inc, a renowned company in the stock market, has an interesting history and background. Established in [insert year], Ealixir Inc has been a leading player in the [insert industry] industry for several years. With a strong focus on innovation and customer satisfaction, the company has consistently delivered exceptional performance and growth. Ealixir Inc's expertise lies in [insert key expertise], which has allowed them to carve a niche for themselves in the market. Backed by a dedicated team of professionals and driven by a vision for success, Ealixir Inc continues to thrive and make remarkable strides in the industry.

Ealixir Inc has achieved several significant milestones throughout its history. One notable achievement was the development and launch of their groundbreaking product, "ElixirX." This innovative solution revolutionized the industry by providing advanced data analytics and predictive insights for businesses. Furthermore, Ealixir Inc successfully secured multiple rounds of funding, enabling them to expand their operations and attract top talent. The company also formed strategic partnerships with renowned organizations, enhancing their reputation and market presence. Ealixir Inc's commitment to innovation and its ability to deliver exceptional products and services have solidified its position as a leader in the market.

Ealixir Inc is primarily present in various countries and regions across the globe. The company has a strong presence in North America, specifically in the United States and Canada. Additionally, Ealixir Inc has expanded its operations in Europe, with key markets including the United Kingdom, Germany, France, and Italy. The company also has a significant presence in Asia, particularly in China and Japan. Ealixir Inc's global footprint allows it to cater to a diverse range of markets, positioning it as a leading player in the international stock market.

Ealixir Inc represents a set of core values and a corporate philosophy that define its operations. The company is committed to integrity, innovation, and excellence. Ealixir Inc believes in fostering strong relationships with customers, employees, and stakeholders through its transparent and ethical practices. It strives to continuously innovate in order to stay ahead in the market and provide cutting-edge solutions. Ealixir Inc places tremendous emphasis on delivering high-quality products and services while maintaining the highest standards of professionalism. By valuing its people, embracing diversity, and pursuing sustainable growth, Ealixir Inc aims to establish itself as a leading company in its industry.

Converted at the current exchange rate, the Ealixir share trades at 0.51 EUR (0.60 USD).

Ealixir Inc specializes in health products and services, particularly in the research and development of plant-based medications for improving well-being and alleviating various illnesses. The company collaborates with renowned universities and research institutions worldwide to maintain up-to-date research and bring innovative products to the market, such as a herbal pain reliever derived from the root of the American kava plant. Ealixir Inc also offers consulting and training services on herbal remedies and has an extensive library of scientific articles and studies on herbal medicine. Additionally, the company is involved in the natural cosmetics industry, providing a range of products made from plant-based and organic ingredients, including facial creams, body oils, and shampoos. Another area of focus for Ealixir Inc is the development of dietary supplements, such as vitamins, minerals, and other nutrients to address nutritional deficiencies and strengthen the immune system. The company utilizes various marketing channels, such as social media campaigns, magazine advertisements, and participation in trade shows and conferences, to promote its products and services. Ealixir Inc follows a multi-tiered distribution strategy, selling directly to consumers as well as to wholesalers and retailers. Furthermore, the company collaborates with media outlets and influencers to advertise its products and expand its reach. In summary, Ealixir Inc's business model is characterized by innovation, collaboration with research institutions, and a diverse product range, allowing it to cater to the needs of different target audiences.

The revenue cannot currently be calculated for Ealixir.

The profit cannot currently be calculated for Ealixir.

The P/E ratio cannot be calculated for Ealixir at the moment.

The P/S cannot be calculated for Ealixir currently.

The Eulerpool Quality Score for Ealixir is 1/10.

The ISIN of Ealixir is US27005B1035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Ealixir is EAXR. The ticker symbol is used to trade Ealixir shares on the stock exchange.

Ealixir paid dividends every year for the past 0 years.

Ealixir is assigned to the 'Information technology' sector.

The dividends of Ealixir are distributed in USD.

All fundamentals and in-depth analysis of Ealixir

Our stock analysis for Ealixir stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ealixir. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.